دورية أكاديمية
Evaluation of " Caterina assay ": An Alternative Tool to the Commercialized Kits Used for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Identification.
العنوان: | Evaluation of " Caterina assay ": An Alternative Tool to the Commercialized Kits Used for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Identification. |
---|---|
المؤلفون: | Orrù G; Department of Surgical Sciences, Molecular Biology Service (MBS), University of Cagliari, 09124 Cagliari, Italy.; Dipartimento Servizi di Diagnosi e Cura, Azienda Ospedaliero-Universitaria di Cagliari (A.O.U.), University of Cagliari, 09024 Cagliari, Italy., Scano A; Department of Surgical Sciences, Molecular Biology Service (MBS), University of Cagliari, 09124 Cagliari, Italy.; Dipartimento Servizi di Diagnosi e Cura, Azienda Ospedaliero-Universitaria di Cagliari (A.O.U.), University of Cagliari, 09024 Cagliari, Italy., Fais S; Department of Surgical Sciences, Molecular Biology Service (MBS), University of Cagliari, 09124 Cagliari, Italy., Loddo M; Dipartimento Servizi di Diagnosi e Cura, Azienda Ospedaliero-Universitaria di Cagliari (A.O.U.), University of Cagliari, 09024 Cagliari, Italy., Carta MG; Department of Medical Sciences and Public Health, University of Cagliari, 09124 Cagliari, Italy., Steri GC; Azienda per la Tutela della Salute (ATS), Aree Socio-Sanitarie Locali (ASSL) of Cagliari, 09131 Cagliari, Italy., Santus S; Azienda per la Tutela della Salute (ATS), Aree Socio-Sanitarie Locali (ASSL) of Cagliari, 09131 Cagliari, Italy., Cappai R; Dipartimento Servizi di Diagnosi e Cura, Azienda Ospedaliero-Universitaria di Cagliari (A.O.U.), University of Cagliari, 09024 Cagliari, Italy., Ferrando ML; Department of Surgical Sciences, Molecular Biology Service (MBS), University of Cagliari, 09124 Cagliari, Italy., Coghe F; Dipartimento Servizi di Diagnosi e Cura, Azienda Ospedaliero-Universitaria di Cagliari (A.O.U.), University of Cagliari, 09024 Cagliari, Italy. |
المصدر: | Pathogens (Basel, Switzerland) [Pathogens] 2021 Mar 10; Vol. 10 (3). Date of Electronic Publication: 2021 Mar 10. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101596317 Publication Model: Electronic Cited Medium: Print ISSN: 2076-0817 (Print) Linking ISSN: 20760817 NLM ISO Abbreviation: Pathogens Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI AG, 2012- |
مستخلص: | Here we describe the first molecular test developed in the early stage of the pandemic to diagnose the first cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Sardinian patients in February-March 2020, when diagnostic certified methodology had not yet been adopted by clinical microbiology laboratories. The " Caterina assay " is a SYBR ® Green real-time reverse-transcription polymerase chain reaction (rRT-PCR), designed to detect the nucleocapsid phosphoprotein (N) gene that exhibits high discriminative variation RNA sequence among bat and human coronaviruses. The molecular method was applied to detect SARS-CoV-2 in nasal swabs collected from 2110 suspected cases. The study article describes the first molecular test developed in the early stage of the declared pandemic to identify the coronavirus disease 2019 (COVID-19) in Sardinian patients in February-March 2020, when a diagnostic certified methodology had not yet been adopted by clinical microbiology laboratories. The assay presented high specificity and sensitivity (with a detection limit ≥50 viral genomes/μL). No false-positives were detected, as confirmed by the comparison with two certified commercial kits. Although other validated molecular methods are currently in use, the Caterina assay still represents a valid and low-cost detection procedure that could be applied in countries with limited economic resources. |
References: | JAMA. 2020 Aug 25;324(8):782-793. (PMID: 32648899) iScience. 2021 Jun 25;24(6):102681. (PMID: 34095780) J Clin Virol. 2020 Aug;129:104510. (PMID: 32570045) Electrophoresis. 2012 Apr;33(7):1215-9. (PMID: 22539325) Nat Biotechnol. 2020 Jul;38(7):870-874. (PMID: 32300245) J Med Virol. 2020 Jun;92(6):546-547. (PMID: 32115732) J Infect Public Health. 2020 Jul;13(7):901-905. (PMID: 32534946) J Mol Diagn. 2020 Dec;22(12):1367-1372. (PMID: 32961315) Hum Genomics. 2020 May 12;14(1):17. (PMID: 32398162) Braz J Microbiol. 2020 Sep;51(3):1117-1123. (PMID: 32767275) Periodontol 2000. 2019 Feb;79(1):178-189. (PMID: 30892769) Theranostics. 2020 Jun 1;10(16):7150-7162. (PMID: 32641984) Clin Chem. 2020 Apr 1;66(4):549-555. (PMID: 32031583) Med Hypotheses. 2020 Aug;141:109786. (PMID: 32361529) J Virol Methods. 2006 Oct;137(1):34-42. (PMID: 16876884) Infect Genet Evol. 2008 Jul;8(4):397-405. (PMID: 17881296) Euro Surveill. 2020 Jan;25(3):. (PMID: 31992387) Materials (Basel). 2020 Nov 26;13(23):. (PMID: 33255977) Microorganisms. 2020 Jul 17;8(7):. (PMID: 32708870) Open Respir Med J. 2020 Mar 16;14:8-9. (PMID: 32509035) J Mol Diagn. 2014 Sep;16(5):477-480. (PMID: 25017792) J Clin Microbiol. 2020 Jul 23;58(8):. (PMID: 32461287) Biology (Basel). 2021 Jan 26;10(2):. (PMID: 33530355) Nat Microbiol. 2020 Apr;5(4):536-544. (PMID: 32123347) Eur Rev Med Pharmacol Sci. 2020 Aug;24(15):8226-8231. (PMID: 32767354) Elife. 2021 Feb 23;10:. (PMID: 33620031) Graefes Arch Clin Exp Ophthalmol. 2020 Oct;258(10):2271-2274. (PMID: 32567041) Clin Chem Lab Med. 2020 Jun 25;58(7):1139-1141. (PMID: 32242831) Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7276-80. (PMID: 1871133) Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):3434-3436. (PMID: 32329810) |
فهرسة مساهمة: | Keywords: COVID-19 detection; DNA folding; N protein; SYBR®Green real-time PCR; melting curve analysis; molecular diagnostic of SARS-CoV-2 |
تواريخ الأحداث: | Date Created: 20210403 Latest Revision: 20231111 |
رمز التحديث: | 20231111 |
مُعرف محوري في PubMed: | PMC7998653 |
DOI: | 10.3390/pathogens10030325 |
PMID: | 33802049 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2076-0817 |
---|---|
DOI: | 10.3390/pathogens10030325 |